Background: The limitations of dissociative bulk omics analysis, sample attrition noise, and evolutionary plasticity data bottlenecks in IDH-mutant glioma R&D.

Conventional static and linear bulk sequencing guidelines rely on a baseline that assumes genetic homogeneity, leading to a critical blind spot in elucidating the dynamic transitions of epigenetic differentiation states exhibited by rare cell clones within the spatially highly heterogeneous tumor microenvironment. In particular, the dissociative structural attrition noise and resistance feedback flux associated with the longitudinal evolutionary process of Isocitrate Dehydrogenase (IDH)-mutant gliomas have hindered the assurance of clinically effective drug concentrations. Existing R&D models, which fail to computationally control the collapse of differentiation topology due to stem cell potency recovery mechanisms, expose limitations in omics architecture and complex genomic data barriers, preventing the tracking of malignant transformation into high-grade tumors, and acting as a bottleneck that frustrates attempts at precision-tailored tumor control.

Discovery: Implementation of a single-cell multi-omics integrated algorithm and demonstration of longitudinal single-cell resolution tensor synchronization.

In this study, we implemented a computational algorithm that precisely integrates single-cell transcriptomic and epigenetic multi-omics data to track the cumulative epigenetic variation profile of longitudinal samples of IDH-mutant brain tumors at the single-cell resolution level. We computationally removed batch effects from the cell extraction process, which degrades the reliability of genomic analysis, and proactively calculated differential equation-based rate constants in a in silico environment by applying the free-energy local minimization law to describe the differentiation energy landscape. This enabled us to synchronize independent tensors at the brain tumor cell resolution scale, demonstrating that widespread DNA hypomethylation is associated with tumor progression and malignant transformation. This epigenetic collapse induces irreversible plasticity transitions in cell differentiation topology, successfully elucidating the emergence of neural stem cell-like states with a resolution that surpasses existing simple models.

Establishment of a numerical simulation backbone for coordinating DNA hypomethylation pathways and establishing a layered model for precise stratification of reversible tumor stem cell homeostasis.

By tracking genome-wide DNA hypomethylation and downstream differentiation signaling pathways, we designed a numerical simulation backbone that can reversibly control tumor cell homeostasis even in abnormal stress microenvironments by up- or down-regulating methylation-regulating gene binding energy constants, which govern the evolutionary rate-limiting steps of the tumor. This layered model, constructed based on individual single-cell level developmental differentiation landscapes and epigenetic matrices, mathematically calculates the probability of identity transition of tumor cells, which often manifests as heterogeneity. By precisely stratifying the patient's molecular phenotype over time and lineage through the omics matrix, we have established a powerful computational medicine framework that can pre-screen and classify the potential for drug resistance in patient populations during pre-clinical trials.

Prospects: Establishing a programmable computational systems biology standard and launching a next-generation IND digital governance system.

The architecture established by the research team will serve as a catalyst for a complete reset of the static drug R&D infrastructure, which has been limited to post-hoc analysis in the past, into a programmable computational systems biology framework based on AI-powered multidimensional tensor models. This will enable multinational pharmaceutical companies and global biotech companies to synchronize genetic gradient correction coefficients with companion diagnostics (CDx) design in the high-throughput screening phase of new drug pipelines, thereby eliminating effective genomic expression variations between different sample batches and establishing a robust genomic R&D governance system. Furthermore, targeted combinatorial control technologies that block methylation plasticity will fully meet the next-generation clinical trial (IND) approval standards and cGMP criteria for large-scale commercial production, serving as a unique master asset that dramatically shortens the timeline for clinical approval evaluation.